press release archive

Rigel to Present at 5th Annual Fortis Bank Biotech Conference on April 27, 2005

South San Francisco, CA - April 22, 2005

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) will present at the 5th Annual Fortis Bank Biotech Conference on Wednesday, April 27, 2005 at 10:00 a.m. British Time at the Four Seasons Hotel in London. James M. Gower, Rigel’s chairman and chief executive officer, will discuss the company’s clinical development and research programs.

About Rigel (www.rigel.com)
Rigel's mission is to become a source of novel, small-molecule drugs to address large, unmet medical needs. We have four research and development programs investigating treatments for asthma/allergy, rheumatoid arthritis, oncology and hepatitis C. Our strategy is to initiate clinical trials with at least one new product candidate annually and to pursue partnerships with pharmaceutical and biotechnology companies for late-stage clinical development and commercialization of those product candidates.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue clinical development of product candidates and the timing thereof and the potential efficacy of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, as well as other risks detailed from time to time in Rigel's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2004. Rigel does not undertake any obligation to update forward-looking statements.